Systemic treatment followed protocols for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, using an aromatase inhibitor and ribociclib, resulting in a favorable clinical and metabolic response. Here, CYP19A1 is linked to breast carcinoma.